These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20483025)

  • 1. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
    de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
    Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
    Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
    Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
    Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
    Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
    Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
    Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
    Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
    Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
    Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
    Lath R; Chacko G; Chandy MJ
    Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
    Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
    Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
    Mastronardi L; Guiducci A; Puzzilli F
    BMC Cancer; 2001; 1():12. PubMed ID: 11570981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
    Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
    Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
    Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
    J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
    Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
    Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence in pituitary adenomas in childhood and adolescence.
    Espay AJ; Azzarelli B; Williams LS; Bodensteiner JB
    J Child Neurol; 2001 May; 16(5):364-7. PubMed ID: 11392522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
    Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
    Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody.
    Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A
    Tumori; 2000; 86(3):229-32. PubMed ID: 10939604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
    Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
    Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
    Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.